Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa
-
By
-
Juling Sia
-
Bernett Lee
-
Hazel H. Oon
-
April 22, 2026
-
Clinical Scorecard: Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Individuals with moderate-to-severe Hidradenitis Suppurativa, including specific age ranges and demographics. |
| Care Setting | |
Key Highlights
- HS is a chronic inflammatory skin disorder with significant comorbidities, including metabolic syndrome and depression.
Guideline-Based Recommendations
Diagnosis
Management
- First-line therapy includes antibiotics; biologics such as adalimumab and secukinumab may be used for severe cases.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Combination of pharmacological therapies, including antibiotics and biologics, and surgical therapies may be required for disease control.
Clinical Best Practices
- Monitor for comorbidities associated with HS, such as obesity, metabolic syndrome, and depression, during treatment.
References
